2022年12月22日

Adlai Nortye有限公司(以下簡稱“Adlai Nortye”),全球生物製藥公司致力於開發創新的腫瘤藥物,今天宣布完成係列D輪融資1億美元。由國投基金管理和Tigermed共同參與此輪融資傳奇明星,無錫生物製劑保健企業,Triwise資本,青島Mukui國聯工業投資田通用交互式等。所得資金將用於加快發展持續的臨床和臨床前計劃,擴大藥物組合通過內部研發能力、許可證、合並、收購,和其他戰略合作。“我們打算開發差異化和創新的全球腫瘤藥物解決未滿足的醫療需求和渴望致命癌症轉變成慢性,最終可治愈的疾病,“Carsten Lu說,總統和首席執行官Adlai Nortye。“這一輪融資Adlai Nortye代表一個重要的裏程碑,我們榮幸繼續獲得支持著名的新的和現有的投資者Adlai Nortye已經演示了一個證實的記錄我們承諾交付前幾輪的市場和投資者。我們將能夠推進我們健壯的療法的發展管道和期待引進越來越多的全球創新治療患者中受益。”"We have strong conviction in innovation and paying close attention to what is trending in the biopharmaceutical industry," said Dazhong Lv, Managing Director of SDIC Fund Management. "Adlai Nortye's strategic vision in global market, dedication to innovation in research, and strong execution capability are what have been attracting us. We are pleased to have the opportunity to lead Adlai Nortye's D round and look forward to the development of multiple first-in-class drugs from the company's innovative pipeline globally and in China." Yan Leng, partner of Legend Star added, "Adlai Nortye is quickly emerging as a leader in the field of oncology and we are delighted to have invested in Adlai Nortye and provided support for the R&D of the company's promising pipeline. Combining innovative research and advanced clinical assets with proven management experience, Adlai Nortye has built an exciting portfolio filled with opportunities. We are excited to join such an experienced and proven management team, an outstanding group of investors, and top-tier pharmaceutical partners to advance the company's pipeline products." Share this article: